| Dear Subscriber, |
| Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories. To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
| Alcohol / Addiction / Illegal Drugs News | |
| Higher Hepatitis C Virus Infection Rate In Massachusetts Among Teenagers And Young Adults Hepatitis C virus (HCV) infection rates among teenagers and young adults are rising significantly in Massachusetts, according to a new CDC report. Experts say it is principally due to needle sharing by illicit drug users. | 07 May 2011 |
| Alzheimer's / Dementia News | |
| Blood Test That Diagnoses Alzheimer's May Soon Be On The Market A blood test that measures the effect of promoting DHEA production can diagnose Alzheimer's disease and may soon hit the market, scientists from the Research Institute of the McGill University Health Centre, Canada announced today. | 07 May 2011 |
| Anxiety / Stress News | |
| IPads Help Reduce Pain And Anxiety In The Children's ER Nurses in the emergency department at NewYork-Presbyterian/Morgan Stanley Children's Hospital are pioneering techniques -- including the use of iPads -- to improve the patient experience by eliminating or minimizing pain. | 07 May 2011 |
| Biology / Biochemistry News | |
| Research Reveals How Cancer-Driving Enzyme Works Cancer researchers at UT Southwestern Medical Center are helping unlock the cellular-level function of the telomerase enzyme, which is linked to the disease's growth.Their latest findings, published in Molecular Cell, demonstrate that telomerase repairs chromosomes in one of two ways depending on whether a cell is dividing normally or if the cell is under stress from enzyme inhibition and could lead to new or improved cancer-fighting therapies that promote inhibition of this enzyme. | 07 May 2011 |
| Cancer / Oncology News | |
| Seve Ballesteros Dies After Long Battle With Brain Cancer Seve Ballesteros died in the early hours of today after a long battle with brain cancer. His family issued a communiqué yesterday evening explaining that his neurological condition had "suffered a severe deterioration". | 07 May 2011 |
| Afinitor (everolimus) For Rare Pancreatic Cancer Approved By FDA Afinitor (everolimus), a medication for patients with PNET (progressive neuroendocrine tumors) in the pancreas whose tumor cannot be surgically removed or whose cancer has metastasized (spread), has been approved by the Food and Drug Administration (FDA). | 07 May 2011 |
| Abbott Receives FDA Approval To Expand Use Of The RX ACCULINK® Carotid Stent System To Patients At Standard Surgical Risk Abbott announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy (surgery). | 07 May 2011 |
| Research Reveals How Cancer-Driving Enzyme Works Cancer researchers at UT Southwestern Medical Center are helping unlock the cellular-level function of the telomerase enzyme, which is linked to the disease's growth.Their latest findings, published in Molecular Cell, demonstrate that telomerase repairs chromosomes in one of two ways depending on whether a cell is dividing normally or if the cell is under stress from enzyme inhibition and could lead to new or improved cancer-fighting therapies that promote inhibition of this enzyme. | 07 May 2011 |
| Cardiovascular / Cardiology News | |
| Abbott Receives FDA Approval To Expand Use Of The RX ACCULINK® Carotid Stent System To Patients At Standard Surgical Risk Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy (surgery). | 07 May 2011 |
| Study Shows Stents Are Superior To Balloons Alone For Patients With Deep Venous Thrombosis Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore. | 07 May 2011 |
| New Device To Support Blood Circulation For Heart Patients Shows Improved Outcomes Compared To Current Treatment A new device designed to assist blood circulation and support blood pressure in high-risk patients undergoing percutaneous coronary intervention (PCI) has shown improved outcomes compared to the standard treatment with an intraaortic balloon pump. | 07 May 2011 |
| New Guidelines For Cardiovascular Genetic Testing An international panel of experts from The Heart Rhythm Society and the European Heart Rhythm Association issued new guideline recommendations for all health care professionals about cardiovascular genetic testing at the Heart Rhythm Society's 32nd Annual Scientific Sessions. | 07 May 2011 |
| Clinical Trials / Drug Trials News | |
| Bayer And Regeneron Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). | 07 May 2011 |
| Conferences News | |
| Varian Medical Systems Spotlights Advanced Radiosurgery Systems At ISRS Congress In Paris Varian Medical Systems (NYSE: VAR) is spotlighting its TrueBeam™ STx with Novalis® Radiosurgery program for fast and precise stereotactic radiosurgery cancer treatments at the International Stereotactic Radiosurgery Society (ISRS) congress in Paris next week. | 07 May 2011 |
| Cosmetic Medicine / Plastic Surgery News | |
| Varian Medical Systems Spotlights Advanced Radiosurgery Systems At ISRS Congress In Paris Varian Medical Systems (NYSE: VAR) is spotlighting its TrueBeam™ STx with Novalis® Radiosurgery program for fast and precise stereotactic radiosurgery cancer treatments at the International Stereotactic Radiosurgery Society (ISRS) congress in Paris next week. | 07 May 2011 |
| Dentistry News | |
| The Mystery Of Burning Mouth Syndrome Most people can relate to the uncomfortable feeling that occurs after scalding their mouth on hot soup or coffee. It's a relief when that burnt feeling subsides after several days. But imagine experiencing that burning sensation all day, every day. | 07 May 2011 |
| Dermatology News | |
| Solta Medical Announces FDA 510(k) Clearance For New Clear + Brilliant Technology Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic skin treatments announced it has received FDA 510(k) clearance of its new Clear + Brilliant laser aesthetic treatment, which will officially launch at the World Congress of Dermatology in Seoul, Korea on May 25, 2011. | 07 May 2011 |
| Endocrinology News | |
| Afinitor (everolimus) For Rare Pancreatic Cancer Approved By FDA Afinitor (everolimus), a medication for patients with PNET (progressive neuroendocrine tumors) in the pancreas whose tumor cannot be surgically removed or whose cancer has metastasized (spread), has been approved by the Food and Drug Administration (FDA). | 07 May 2011 |
| Eye Health / Blindness News | |
| Bayer And Regeneron Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). | 07 May 2011 |
| Genetics News | |
| New Guidelines For Cardiovascular Genetic Testing An international panel of experts from The Heart Rhythm Society and the European Heart Rhythm Association issued new guideline recommendations for all health care professionals about cardiovascular genetic testing at the Heart Rhythm Society's 32nd Annual Scientific Sessions. | 07 May 2011 |
| Happiness Gene Located A gene which regulates the movement of serotonin in the brain has been labeled the "happiness gene" by researchers from the London School of Economics and reported in the Journal of Human Genetics. | 07 May 2011 |
| Heart Disease News | |
| Abbott Receives FDA Approval To Expand Use Of The RX ACCULINK® Carotid Stent System To Patients At Standard Surgical Risk Abbott announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy (surgery). | 07 May 2011 |
| Abbott Receives FDA Approval To Expand Use Of The RX ACCULINK® Carotid Stent System To Patients At Standard Surgical Risk Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy (surgery). | 07 May 2011 |
| Study Shows Stents Are Superior To Balloons Alone For Patients With Deep Venous Thrombosis Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore. | 07 May 2011 |
| New Device To Support Blood Circulation For Heart Patients Shows Improved Outcomes Compared To Current Treatment A new device designed to assist blood circulation and support blood pressure in high-risk patients undergoing percutaneous coronary intervention (PCI) has shown improved outcomes compared to the standard treatment with an intraaortic balloon pump. | 07 May 2011 |
| New Guidelines For Cardiovascular Genetic Testing An international panel of experts from The Heart Rhythm Society and the European Heart Rhythm Association issued new guideline recommendations for all health care professionals about cardiovascular genetic testing at the Heart Rhythm Society's 32nd Annual Scientific Sessions. | 07 May 2011 |
| IT / Internet / E-mail News | |
| Hannibal Regional Healthcare System Selects Allscripts Acute Care Electronic Health Record To Support Connected Community Of Health Hannibal Regional Healthcare System, which operates a not-for-profit community hospital in northeast Missouri, has selected the Sunrise Enterprise™ suite of solutions from Allscripts (NASDAQ: MDRX). | 07 May 2011 |
| Liver Disease / Hepatitis News | |
| Higher Hepatitis C Virus Infection Rate In Massachusetts Among Teenagers And Young Adults Hepatitis C virus (HCV) infection rates among teenagers and young adults are rising significantly in Massachusetts, according to a new CDC report. Experts say it is principally due to needle sharing by illicit drug users. | 07 May 2011 |
| Medical Devices / Diagnostics News | |
| New Device To Support Blood Circulation For Heart Patients Shows Improved Outcomes Compared To Current Treatment A new device designed to assist blood circulation and support blood pressure in high-risk patients undergoing percutaneous coronary intervention (PCI) has shown improved outcomes compared to the standard treatment with an intraaortic balloon pump. | 07 May 2011 |
| Medicare / Medicaid / SCHIP News | |
| Quest Diagnostics Care360 EHR Customer Successfully Completes Meaningful Use Attestation To Receive The Medicare EHR Incentive Quest Diagnostics® (NYSE: DGX) announced that Care360 user Paulo Andre, M.D., a neurologist in Framingham, MA, was the first Care360 EHR customer to successfully complete the attestation process for demonstrating Meaningful Use of an electronic health record with an ONC-ATCB certified complete EHR* in accordance with the Centers for Medicare and Medicaid Services (CMS) EHR incentive program. | 07 May 2011 |
| MRSA / Drug Resistance News | |
| FDA Clears First Test To Quickly Diagnose And Distinguish MRSA And MSSA The U.S. Food and Drug Administration cleared the first test for Staphylococcus aureus (S.aureus) infections that is able to quickly identify whether the bacteria are methicillin resistant (MRSA) or methicillin susceptible (MSSA). | 07 May 2011 |
| Neurology / Neuroscience News | |
| Seve Ballesteros Dies After Long Battle With Brain Cancer Seve Ballesteros died in the early hours of today after a long battle with brain cancer. His family issued a communiqué yesterday evening explaining that his neurological condition had "suffered a severe deterioration". | 07 May 2011 |
| Blood Test That Diagnoses Alzheimer's May Soon Be On The Market A blood test that measures the effect of promoting DHEA production can diagnose Alzheimer's disease and may soon hit the market, scientists from the Research Institute of the McGill University Health Centre, Canada announced today. | 07 May 2011 |
| Happiness Gene Located A gene which regulates the movement of serotonin in the brain has been labeled the "happiness gene" by researchers from the London School of Economics and reported in the Journal of Human Genetics. | 07 May 2011 |
| Nursing / Midwifery News | |
| Nurse Has Seen Change And History Over 50-Year Career As she completes her unprecedented 50th year of work as a nurse this July, Norma Salahshour asserts that very little has changed since she was a fresh-faced graduate beginning her first job.Although The Methodist Hospital and nursing itself have evolved radically over the years, Salahshour just finds the same inspiration to come to work today as she did five decades ago. | 07 May 2011 |
| Nutrition / Diet News | |
| To Avoid Adult Obesity Stop Bottle-Feeding At 18 Months If you want to reduce your baby's chances of becoming an obese adult you should not continue bottle-feeding him/her beyond 12 to 18 months of age, researchers from the Albert Einstein College of Medicine reported in the Journal of Pediatrics. | 07 May 2011 |
| Obesity / Weight Loss / Fitness News | |
| To Avoid Adult Obesity Stop Bottle-Feeding At 18 Months If you want to reduce your baby's chances of becoming an obese adult you should not continue bottle-feeding him/her beyond 12 to 18 months of age, researchers from the Albert Einstein College of Medicine reported in the Journal of Pediatrics. | 07 May 2011 |
| Pain / Anesthetics News | |
| Pediatric Liquid Acetaminophen To Be Just One Concentration, To Prevent Overdose Risk Having various concentrations of pediatric liquid acetaminophen medications has the disadvantage in that parents may give their child excessive doses. The CHPA (Consumer Healthcare Products Association) has announced plans by makers of OTC (over-the-counter) medications to have just one concentration. | 07 May 2011 |
| IPads Help Reduce Pain And Anxiety In The Children's ER Nurses in the emergency department at NewYork-Presbyterian/Morgan Stanley Children's Hospital are pioneering techniques -- including the use of iPads -- to improve the patient experience by eliminating or minimizing pain. | 07 May 2011 |
| Pancreatic Cancer News | |
| Afinitor (everolimus) For Rare Pancreatic Cancer Approved By FDA Afinitor (everolimus), a medication for patients with PNET (progressive neuroendocrine tumors) in the pancreas whose tumor cannot be surgically removed or whose cancer has metastasized (spread), has been approved by the Food and Drug Administration (FDA). | 07 May 2011 |
| Novartis Gains FDA Approval For Afinitor® As First New Treatment In Nearly Three Decades For Patients With Advanced Pancreatic NET Novartis Pharmaceuticals Corporation ("Novartis") announced that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4). | 07 May 2011 |
| FDA Approves Novartis Drug Afinitor To Treat Pancreatic Neuroendocrine Tumors Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. Neuroendocrine tumors make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less aggressive than the more common form of pancreatic cancer, pancreatic adenocarcinoma. | 07 May 2011 |
| Pediatrics / Children's Health News | |
| Pediatric Liquid Acetaminophen To Be Just One Concentration, To Prevent Overdose Risk Having various concentrations of pediatric liquid acetaminophen medications has the disadvantage in that parents may give their child excessive doses. The CHPA (Consumer Healthcare Products Association) has announced plans by makers of OTC (over-the-counter) medications to have just one concentration. | 07 May 2011 |
| To Avoid Adult Obesity Stop Bottle-Feeding At 18 Months If you want to reduce your baby's chances of becoming an obese adult you should not continue bottle-feeding him/her beyond 12 to 18 months of age, researchers from the Albert Einstein College of Medicine reported in the Journal of Pediatrics. | 07 May 2011 |
| IPads Help Reduce Pain And Anxiety In The Children's ER Nurses in the emergency department at NewYork-Presbyterian/Morgan Stanley Children's Hospital are pioneering techniques -- including the use of iPads -- to improve the patient experience by eliminating or minimizing pain. | 07 May 2011 |
| Pharma Industry / Biotech Industry News | |
| Bayer And Regeneron Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). | 07 May 2011 |
| Ferring Pharmaceuticals To Support Great Prostate Cancer Challenge® Events Across The Country In National Effort To End Prostate Cancer Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), a hormone antagonist therapy for advanced prostate cancer, has joined the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge®, the fastest growing men's health event series in the United States. | 07 May 2011 |
| Novartis Gains FDA Approval For Afinitor® As First New Treatment In Nearly Three Decades For Patients With Advanced Pancreatic NET Novartis Pharmaceuticals Corporation ("Novartis") announced that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4). | 07 May 2011 |
| Rigel Assumes Development Responsibility For Inhaled Asthma Therapy Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. | 07 May 2011 |
| Pharmacy / Pharmacist News | |
| Pediatric Liquid Acetaminophen To Be Just One Concentration, To Prevent Overdose Risk Having various concentrations of pediatric liquid acetaminophen medications has the disadvantage in that parents may give their child excessive doses. The CHPA (Consumer Healthcare Products Association) has announced plans by makers of OTC (over-the-counter) medications to have just one concentration. | 07 May 2011 |
| Prostate / Prostate Cancer News | |
| Ferring Pharmaceuticals To Support Great Prostate Cancer Challenge® Events Across The Country In National Effort To End Prostate Cancer Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), a hormone antagonist therapy for advanced prostate cancer, has joined the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge®, the fastest growing men's health event series in the United States. | 07 May 2011 |
| Psychology / Psychiatry News | |
| Happiness Gene Located A gene which regulates the movement of serotonin in the brain has been labeled the "happiness gene" by researchers from the London School of Economics and reported in the Journal of Human Genetics. | 07 May 2011 |
| Radiology / Nuclear Medicine News | |
| Varian Medical Systems Spotlights Advanced Radiosurgery Systems At ISRS Congress In Paris Varian Medical Systems (NYSE: VAR) is spotlighting its TrueBeam™ STx with Novalis® Radiosurgery program for fast and precise stereotactic radiosurgery cancer treatments at the International Stereotactic Radiosurgery Society (ISRS) congress in Paris next week. | 07 May 2011 |
| Regulatory Affairs / Drug Approvals News | |
| Abbott Receives FDA Approval To Expand Use Of The RX ACCULINK® Carotid Stent System To Patients At Standard Surgical Risk Abbott announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy (surgery). | 07 May 2011 |
| Solta Medical Announces FDA 510(k) Clearance For New Clear + Brilliant Technology Solta Medical, Inc. (Nasdaq: SLTM), the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic skin treatments announced it has received FDA 510(k) clearance of its new Clear + Brilliant laser aesthetic treatment, which will officially launch at the World Congress of Dermatology in Seoul, Korea on May 25, 2011. | 07 May 2011 |
| Abbott Receives FDA Approval To Expand Use Of The RX ACCULINK® Carotid Stent System To Patients At Standard Surgical Risk Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy (surgery). | 07 May 2011 |
| FDA Clears First Test To Quickly Diagnose And Distinguish MRSA And MSSA The U.S. Food and Drug Administration cleared the first test for Staphylococcus aureus (S.aureus) infections that is able to quickly identify whether the bacteria are methicillin resistant (MRSA) or methicillin susceptible (MSSA). | 07 May 2011 |
| Novartis Gains FDA Approval For Afinitor® As First New Treatment In Nearly Three Decades For Patients With Advanced Pancreatic NET Novartis Pharmaceuticals Corporation ("Novartis") announced that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4). | 07 May 2011 |
| FDA Approves Novartis Drug Afinitor To Treat Pancreatic Neuroendocrine Tumors Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. Neuroendocrine tumors make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less aggressive than the more common form of pancreatic cancer, pancreatic adenocarcinoma. | 07 May 2011 |
| Respiratory / Asthma News | |
| Rigel Assumes Development Responsibility For Inhaled Asthma Therapy Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. | 07 May 2011 |
| Sports Medicine / Fitness News | |
| Seve Ballesteros Dies After Long Battle With Brain Cancer Seve Ballesteros died in the early hours of today after a long battle with brain cancer. His family issued a communiqué yesterday evening explaining that his neurological condition had "suffered a severe deterioration". | 07 May 2011 |
| Tropical Diseases News | |
| Malaria Mosquitoes Accurately Find Their Way To Smelly Feet Malaria mosquitoes utilise CO2 from exhaled air to localise humans from afar. In the vicinity of their preferred host they alter their course towards the human feet. Researcher Remco Suer discovered how female malaria mosquitoes use foot odours in the last meters to guide them to their favoured biting place. | 07 May 2011 |
| Urology / Nephrology News | |
| Ferring Pharmaceuticals To Support Great Prostate Cancer Challenge® Events Across The Country In National Effort To End Prostate Cancer Ferring Pharmaceuticals Inc., the makers of FIRMAGON® (degarelix for injection), a hormone antagonist therapy for advanced prostate cancer, has joined the race to end prostate cancer as an official sponsor of the Great Prostate Cancer Challenge®, the fastest growing men's health event series in the United States. | 07 May 2011 |
| You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y . |
Tidak ada komentar:
Posting Komentar